- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
March 4, 2021Robins Kaplan Files Class Action Against Martin Shkreli and His Former Companies on Behalf of Blue Cross and Blue Shield of Minnesota
-
March 1, 2021Amy Churan Named an Insurance Trailblazer by National Law Journal
-
March 1, 2021Firm, Partner Recognized by Managing IP
-
March, 9, 2021The New Frontier of Software License Disputes
-
March 9, 2021Health Care Antitrust under President Biden
-
March 11, June 10, and October 7, 2021New York Women in Antitrust Group Spotlight Series
-
Winter 2021Pro Bono Publico–For The Public Good
-
Winter 2021The Case for Charitable Giving
-
Winter 2021The Fictional Wealth Disputes That We Took In and Learned From in 2020
-
March 5, 2021Financial Daily Dose 3.5.2021 | Top Story: Powell Tries to Sooth Jumpy Markets Fearing Weak Jobs Report
-
March 4, 2021Financial Daily Dose 3.4.2021 | Top Story: Google Shakes Up Digital Ad Industry by Phasing Out Web Tracking
-
March 3, 2021Financial Daily Dose 3.3.2021 | Top Story: Rare Merck-J&J Partnership to Boost U.S. Vaccine Production
Find additional firm contact information for press inquiries.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Represented Blues plans and other health insurers in litigation against drug manufacturers for overpayments made for the prescription drug buspar
Represented Blues plans and other health insurers in litigation against drug manufacturers for overpayments made for the prescription drug buspar on claims which included allegations of antitrust violations arising from manufacturers’ use of patents and the FDA regulations in conjunction with the Hatch-Waxman Act to keep generics out of the market, settlement obtained for plaintiffs.
Anthem Blue Cross Blue Shield, Blue Cross and Blue Shield of Florida, Inc., Blue Cross and Blue Shield of Louisiana, Blue Cross and Blue Shield of Massachusetts, Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Minnesota, Blue Cross Blue Shield of Nebraska, Blue Cross Blue Shield of Oklahoma, Blue Cross Blue Shield of Tennessee, Blue Shield of California, carefirst, Inc., Excellus Health Plan, Inc., The Guardian Life Insurance Company of America, Hawaii Medical Service Association, Health Care Service Corporation, Horizon Blue Cross Blue Shield of New Jersey, Humana, Inc., Mutual of Omaha, Regence Blue Shield of Idaho, Wellchoice, Inc., Wellmark, Inc. V. Bristol-Myers Squibb, et al
Anthem Blue Cross Blue Shield, Blue Cross and Blue Shield of Florida, Inc., Blue Cross and Blue Shield of Louisiana, Blue Cross and Blue Shield of Massachusetts, Blue Cross Blue Shield of Michigan, Blue Cross Blue Shield of Minnesota, Blue Cross Blue Shield of Nebraska, Blue Cross Blue Shield of Oklahoma, Blue Cross Blue Shield of Tennessee, Blue Shield of California, carefirst, Inc., Excellus Health Plan, Inc., The Guardian Life Insurance Company of America, Hawaii Medical Service Association, Health Care Service Corporation, Horizon Blue Cross Blue Shield of New Jersey, Humana, Inc., Mutual of Omaha, Regence Blue Shield of Idaho, Wellchoice, Inc., Wellmark, Inc. V. Bristol-Myers Squibb, et al
Past results are reported to provide the reader with an indication of the type of litigation we practice. They do not and should not be construed to create an expectation of result in any other case, as all cases are dependent upon their own unique fact situation and applicable law.
Similar Results
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.